Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial.

Even so, the highly significant correlation between absolute change in vertebral strength and absolute change in either vBMD ( R 2 = 0.56–0.67 for the two treatments) or BMC ( R 2 = 0.52–0.76) indicates that an appreciable portion of the change in vertebral strength can be directly attributed to the underlying changes in vBMD and BMC.

also in 132,142 other papers

Trabecular vBMD tended to increase with alendronate but the LS mean gains did not reach statistical significance at any time point (Figure 2 C , Table 2 ).

also in 111,027 other papers